iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

USFDA flags several issues at Aurobindo Pharma’s Anakapalli plant

30 Jun 2023 , 10:14 AM

Authorities from the US Food and Drug Administration discovered numerous issues at a facility owned by one of India’s largest pharmaceutical companies.

According to a USFDA report, auditors discovered ‘deficient’ manufacturing equipment cleaning and storage controls during a visit to an Aurobindo Pharma Ltd. plant in Anakapalli, Southern India, last month. At the facility that manufactures specific active pharmaceutical ingredients, the essential raw materials for creating pharmaceuticals, sampling equipment wasn’t kept clean and maintained to prevent contamination.

The report stated that the creation of adequate and scientifically sound specifications, intended to ensure that drug products comply to acceptable standards of identity, quality, and purity, was also left out of laboratory controls. The report added that the auditors also noticed raw materials being kept in extremely hot and humid circumstances and not in accordance with label storage standards during a warehouse walk-through.

The FDA normally waits to make a decision until it has received a company’s plan to resolve problems. According to a presentation made to investors in August, the Anakapalli factory creates APIs for cardiovascular and anti-fungal medicines.

Aurobindo, a manufacturer of semi-synthetic penicillin, was established in 1986 by P.V. Ramprasad Reddy and K. Nityananda Reddy and has its headquarters in Hyderabad, India’s pharmaceutical capital. Since then, it has grown to export medicines to more than 150 nations, with international markets accounting for 90% of its yearly sales of almost $3 billion. APIs account for 15% of its total sales. 

The company has already been ordered to fix problems. Its Doultabad factory received a warning letter in January of last year, one of the agency’s most severe enforcement actions that can result in import restrictions and delays in product approvals. According to the FDA, the plant produced contaminated API, and repeated failures ‘demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.’

On a call with business analysts last month, Aurobindo’s chief financial officer Santhanam Subramanian stated that the organization is working to have the warning letter ‘cleared.’

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Aurobindo Pharma
  • USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

SBI Card Q4 Profit Slips 20%
25 Apr 2025|11:17 PM
HUL Q4 Net Profit Rises to ₹2,493 Crore
25 Apr 2025|10:59 PM
Sensex and Nifty in Red on April 25, 2025
25 Apr 2025|02:08 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.